Profile to raise $40 million for smart inhaler:
This article was originally published in Clinica
Profile Therapeutics plans to raise £25.5 million ($40 million) on the London Stock Exchange. The Bognor Regis, Sussex-based company is developing inhaled drug delivery systems, based around its Adaptive Aerosol Delivery technology, which produces reproducible and precise doses by adapting to patients' breathing patterns. The company, which began as an inhaler distributor in 1977, launched its first product, the HaloLite system, in 1998. Its present turnover is around £10 million and the flotation, due for March 31, values the company at £81 million.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.